SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Preventive Visit — Elvis Presley

PatientElvis Presley
Date of birth1987-01-08
IdentifiersMRN HR-ML003-SYN; SSN (made up) 000-03-4417
Document date2026-08-14
AuthorColeman Ashby-Nakagawa, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Periodic adult preventive visit. [S]

History of Present Illness

Mr. Presley is a 39-year-old singer with opioid use disorder on buprenorphine, a benzodiazepine use disorder on a slow diazepam taper, stage 2 hypertension, obesity with prediabetes, obstructive sleep apnea on CPAP, opioid-induced constipation and glaucoma, who comes for his yearly preventive visit one week after his three-week review and five days before a Las Vegas engagement. He has taken buprenorphine 16 mg every morning without withdrawal and with few cravings. He took the first diazepam step, to 36 mg a day, a week ago and noticed only slightly worse sleep for two nights. He took his first tirzepatide dose a week ago and had mild nausea for a day. He uses CPAP most nights and feels more awake in the afternoon. His bowels open every one to two days. He has not had a tetanus booster in more than ten years and has never been tested for HIV or hepatitis. [S]

ElementDetail
VisitPeriodic adult preventive visit, age 39
Buprenorphine16 mg daily for four weeks; few cravings
Diazepam36 mg a day since one week ago
TirzepatideFirst 2.5 mg dose a week ago; mild nausea for a day
MoodPHQ-9 5; item 9 scored 0
MedicinesBuprenorphine with naloxone 16 mg daily; diazepam 36 mg a day; amlodipine with valsartan; tirzepatide 2.5 mg weekly; polyethylene glycol; latanoprost; naloxone spray on hand

Health risk assessment. Completed by the patient on a tablet in the waiting room and reviewed with him by Dr. Ashby-Nakagawa. [S]

DomainFinding
Self-rated healthFair, and better than a month ago
PsychosocialBusy professional life; close friends who work with him; worried about how the engagement will go during treatment
AlcoholNone; AUDIT-C 0
TobaccoNever
Other substancesOnly the medicines prescribed by this clinic since intake; DAST-10 7 at intake, now in treatment
Physical activityKarate practice twice a week and walks on the grounds most days
NutritionMoving the main meal earlier; fewer late-night meals
SleepSeven to eight hours with CPAP; less afternoon sleepiness
Safety at homeFeels safe; firearms now locked and unloaded with ammunition separate
Road safetyWears a seat belt; not driving himself until the sleepiness has resolved
Activities of daily livingIndependent
Hearing and visionWears tinted glasses for light sensitivity; ophthalmology follow-up planned next month
Oral healthDental visit in the past year

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy improving; weight down 1.4 kg since intake
EyesNegativeNo eye pain, halos or change in vision
Ears, nose, mouth, and throatNegativeNo dry mouth from CPAP
CardiovascularNegativeNo chest pain, palpitations or ankle swelling
RespiratoryNegativeNo cough or breathlessness; snoring stopped on CPAP
GastrointestinalPositiveMild nausea for a day after the first tirzepatide dose; bowels every one to two days
GenitourinaryNegativeNo urinary symptoms
MusculoskeletalPositiveOccasional neck and back stiffness after practice
IntegumentaryNegativeNo rash or injection-site reaction
NeurologicalNegativeNo tremor, headaches or numbness
PsychiatricNegativePHQ-9 5; no thoughts of suicide or self-harm; cravings low

11 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Hydromorphone 4 mg oral tablet, prescribed elsewhere as one tablet every four to six hours as needed for back and neck pain; taking about five a day (20 mg, 100 MME); continued by this clinic only, at the verified dose and seven days at a time, until the addiction medicine consultationUp to five tablets a day; seven-day supplyOral route2026-07-10 to 2026-07-17completedS
Oxycodone 10 mg and acetaminophen 325 mg oral tablet, prescribed by a second prescriber; taking about three a day (45 MME); continued by this clinic only, seven days at a time, until the consultationUp to three tablets a day; seven-day supplyOral route2026-07-10 to 2026-07-17completedS
Diazepam 10 mg oral tablet, one tablet three times daily, prescribed elsewhere for anxiety; continued by this clinic only, seven days at a timeOne tablet three times daily; seven-day supplyOral route2026-07-10 to 2026-07-17completedS
Alprazolam 1 mg oral tablet, up to three a day as needed, prescribed by a fourth prescriber while on tour; continued by this clinic only, at the verified dose, seven days at a timeUp to three tablets a day; seven-day supplyOral route2026-07-10 to 2026-07-17completedS
Phentermine 37.5 mg oral tablet each morning, prescribed by a weight clinic; stopped today because of high blood pressure and his glaucomaStoppedOral route2026-07-10 to 2026-07-10completedS
Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologistOne drop in each eye at bedtimeOphthalmic route2026-07-10activeS
Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bagOne spray for a suspected overdose; call 911Nasal route2026-07-10activeS
Polyethylene glycol 3350, 17 g powder in a glass of water once daily17 g in water once dailyOral route2026-07-10activeS
Senna 8.6 mg oral tablet, two tablets at bedtimeTwo tablets at bedtimeOral route2026-07-10 to 2026-08-07completedS
Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic onlyTwo films once daily, or one film twice dailySublingual route2026-07-17activeS
Diazepam 10 mg oral tablet, one tablet four times daily (40 mg a day), replacing both diazepam 10 mg three times daily and alprazolam; held steady until buprenorphine is stableOne tablet four times daily; seven-day supplyOral route2026-07-17 to 2026-08-07completedS
Diazepam 10 mg oral tablet, one tablet three times daily, with diazepam 2 mg tablets for the taper steps; dispensed two weeks at a timeOne tablet three times daily with the 2 mg tablets as scheduledOral route2026-08-07activeS
Diazepam 2 mg oral tablet on the written taper schedule: three a day (36 mg a day in all) from the three-week visit, one a day (32 mg) from the ten-week visit, stopped at four months (30 mg)Per the written taper scheduleOral route2026-08-07 to 2026-10-28completedS
Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-07-17activeS
Tirzepatide 2.5 mg/0.5 mL auto-injector, 2.5 mg under the skin once weekly2.5 mg once weeklySubcutaneous route2026-08-07 to 2026-09-23completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-08-14Body height183cmS
2026-08-14Body weight107.6kgS
2026-08-14Body mass index (BMI) [Ratio]32.1kg/m2S
2026-08-14Systolic blood pressure126mm[Hg]S
2026-08-14Diastolic blood pressure80mm[Hg]S
2026-08-14Heart rate74/minS
2026-08-14Respiratory rate14/minS
2026-08-14Body temperature36.6CelS
2026-08-14Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-14Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
2026-08-14Cholesterol [Mass/volume] in Serum or Plasma214mg/dL<=199 mg/dLHighS
2026-08-14Cholesterol in HDL [Mass/volume] in Serum or Plasma38mg/dL>=40 mg/dLLowS
2026-08-14Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation140mg/dL<=129 mg/dLHighS
2026-08-14Triglyceride [Mass/volume] in Serum or Plasma180mg/dL<=149 mg/dLHighS

Physical Exam

Vital signs recorded on 2026-08-14; see the Vital Signs section. [S]

SystemFinding
ConstitutionalWell; weight 107.6 kg, BMI 32.1; blood pressure 126/80; pulse 74
EyesPupils equal and reactive; no redness
NeckCircumference 44 cm; no thyroid enlargement
CardiovascularRegular rhythm; no murmur; no edema
RespiratoryClear
AbdomenSoft, non-tender; liver edge not palpable; no distension
SkinInjection site clean; no track marks
NeurologicalNormal; no tremor

Problems

ProblemClinical statusVerificationCodeProvenance
Fatigue, weight gain of about 14 kg in two years, constipation with a bowel movement every five to seven days, loud snoring with daytime sleepiness, and high blood pressure readings, in a man taking two opioids, two benzodiazepines and an appetite suppressant from five prescribers; under evaluation with addiction medicine, a sleep study and home blood pressure readingsresolvedconfirmed R53.83S — Synthetic presenting problem anchored to the documented prescribed drugs and weight gain; superseded when the consultation and tests made the diagnoses.
Obesity, class 1 (BMI 32.5), with prediabetes (hemoglobin A1c 5.8%); recorded without stigma; weight gain began with long touring schedules, night eating after shows and an appetite suppressant that stopped workingactiveconfirmed E66.811S — Synthetic modern diagnosis anchored to his documented weight gain.
Glaucoma secondary to steroids, both eyes, mild stage, after an acute angle-closure episode treated years ago; intraocular pressure controlled on latanoprost under his ophthalmologist; anticholinergic and sympathomimetic drugs to be avoidedactiveconfirmed H40.63X1S — Synthetic modern diagnosis anchored to his documented glaucoma and the retrospective interpretation of it as steroid-induced; not a claim about his real eyes.
Opioid use disorder, severe, with prescription opioids from more than one prescriber (seven DSM-5-TR criteria, tolerance and withdrawal counted because the opioids were not taken as prescribed); on buprenorphine from the consultation; synthetic modern episode linked to his documented withdrawal from narcotic drugs and prescribed painkillersactiveconfirmed F11.20S — Synthetic modern diagnosis made at the addiction medicine consultation; person-first language; not a claim about his real diagnosis.
Sedative, hypnotic, or anxiolytic use disorder (benzodiazepines), moderate (five DSM-5-TR criteria), with two benzodiazepines from two prescribers; combined into diazepam and tapering slowly; synthetic modern episode linked to his documented prescribed sedativesactiveconfirmed F13.20S — Synthetic modern diagnosis made at the consultation; not a claim about his real diagnosis.
Hypertension, stage 2, confirmed by a home average of 146/94 a week after stopping phentermine; ECG and urine albumin normalactiveconfirmed I10S — Synthetic modern diagnosis confirmed with home readings, anchored to his documented hypertension.
Obstructive sleep apnea, moderate (apnea-hypopnea index 26 an hour, central apnea index 4, oxygen nadir 80% on in-laboratory polysomnography), worsened by opioids and benzodiazepines; on CPAPactiveconfirmed G47.33S — Synthetic modern diagnosis from a synthetic sleep study.
Opioid-induced constipation (Rome IV), improving after the change to buprenorphine; no alarm featuresactiveconfirmed K59.03S — Synthetic modern diagnosis anchored to his documented blockage of the colon; not a claim about megacolon.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Blood pressure screeningCompleted today126/80 mmHg on treatment; home average 128/82
Lipid screening and cardiovascular riskCompleted todayTotal cholesterol 214, HDL 38, LDL 140, triglycerides 180 mg/dL; low 10-year risk; statin not indicated at 39
Diabetes screeningUp to dateHemoglobin A1c 5.8% at intake, prediabetes; treated with weight loss
Obesity behavioral counselingCompleted todayBMI 32.1; intensive counseling with a dietitian arranged
Unhealthy drug use screeningUp to dateDAST-10 7 at intake; in treatment
Unhealthy alcohol useUp to dateAUDIT-C 0 at intake
Tobacco useNot indicatedNever used tobacco
Depression screeningCompleted todayPHQ-9 5, item 9 scored 0
HIV screeningOrderedOnce for all adults; drawn today with his agreement
Hepatitis C screeningOrderedOnce for all adults; drawn today
Hepatitis B screeningOrderedTriple panel once for all adults; drawn today
Colorectal cancer screeningNot indicatedBegins at 45
Tetanus, diphtheria, and pertussisCompleted todayTdap given today; last booster more than ten years ago
Hepatitis B vaccineDueRecommended for adults 19 to 59; to start once today's serology shows he is not immune
Influenza vaccineDueWhen the autumn vaccine is available
COVID-19 vaccineDueDiscussed under shared clinical decision-making; to decide in the autumn
Eye examinationUp to dateUnder his ophthalmologist's care for glaucoma; next visit next month

Immunizations given today: Tdap vaccine; last tetanus booster more than ten years ago [S]

Guideline basis: Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022); Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions (2018); Unhealthy Drug Use: Screening (2020); Adult Immunization Schedule by Age (2026)

Follow-up: Las Vegas engagement with weekly video visits; ten-week review after he returns. HIV, hepatitis C and hepatitis B results by phone. Next preventive visit in one year. Next scheduled visit 2026-09-23: ten-week review after the Las Vegas engagement and a back strain: buprenorphine, the taper, weight treatment, sleep apnea and planning for a three-week tour. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 20 minutes, with his consent. He named a health care agent, a long-time friend who works with him, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. He said that what matters most to him is being able to sing and to be there for the people who depend on him, and that he would want full treatment, including resuscitation and breathing support, after an overdose or other sudden illness. The plan will be revisited yearly or after any serious illness. [S]